Trials
1 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could…”In the company’s words, NCT06421636 on ClinicalTrials.gov
Other drugs for Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- CTX001Vertex Pharmaceuticals · Phase 3
- Vebeglogene autotemcelLantu Biopharma · Phase 1/2
- BRL-101Bioray Laboratories · Phase 1/2
- 9MW3011Mabwell · Phase 1
- LuspaterceptCelgene · Marketed (Phase 4 trial)
Coming up1
- 3 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 3 Dec 2026 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | |
| Phase 1Completed | 29 Aug 2023 | A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026